Evidence map›Paper›PMID 28636593›Full record

ArticleNature2017

T cells from patients with Parkinson's disease recognize α-synuclein peptides.

David Sulzer, Roy N Alcalay, Francesca Garretti, Lucien Cote, Ellen Kanter, Julian Agin-Liebes, Christopher Liong, Curtis McMurtrey, William H Hildebrand, Xiaobo Mao and 14 more

Erratum issued Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04239079 (Autoimmune Features of Neurodegenerative Disorders), which is not on this map. Cited by 525 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
525citing papers in PubMed, 1 pooled it
47.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04239079 recruitingnot on this mapstarted 2019, after this paper: background citation

Autoimmune Features of Neurodegenerative Disorders

TypeobservationalSponsorColumbia UniversityRan2019 to 2028Enrolled120ConditionsParkinson Disease, Alzheimer Disease, Mild Cognitive Impairment
3 · Its place in the literature

Who cites it

525 citing papers in PubMed, 1 synthesis or guideline pooled it, 864 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Progress of Immunotherapies in Parkinson's Disease.CNS neuroscience & therapeutics · 2026
    Review
  19. Review
  20. Review

465 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 2 countries.

David SulzerDepartments of Psychiatry, Columbia University, Division of Molcular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, USA.
Roy N AlcalayDepartment of Neurology, Columbia University, New York, New York 10032, USA.
Francesca GarrettiDepartments of Psychiatry, Columbia University, Division of Molcular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, USA.
Lucien CoteDepartment of Neurology, Columbia University, New York, New York 10032, USA.
Ellen KanterDepartments of Psychiatry, Columbia University, Division of Molcular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, USA.
Julian Agin-LiebesDepartments of Psychiatry, Columbia University, Division of Molcular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, USA.
Christopher LiongDepartment of Neurology, Columbia University, New York, New York 10032, USA.
Curtis McMurtreyDepartment of Microbiology and Immunology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA.
William H HildebrandDepartment of Microbiology and Immunology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA.
Xiaobo MaoNeuroregeneration and Stem Cell Program, Institute for Cell Engineering and the Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Valina L DawsonNeuroregeneration and Stem Cell Program, Institute for Cell Engineering and the Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Ted M DawsonNeuroregeneration and Stem Cell Program, Institute for Cell Engineering and the Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Carla OseroffDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
John PhamDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
Myles B DillonDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
Chelsea CarpenterDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
Daniela WeiskopfDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
Elizabeth PhillipsInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia 6150, Australia.
Simon MallalInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia 6150, Australia.
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
April FrazierDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
Cecilia S Lindestam ArlehamnDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
La Jolla Institute for Immunology · USColumbia University · USJohns Hopkins Medicine · USUniversity of Oklahoma · USJohns Hopkins University · USMurdoch University · AUNew York Psychoanalytic Society and Institute · US

Funding

Understanding Mechanisms of a-synuclein pathologyP50NS038377 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KO, HANSEOK · 1998 to 2019
$38.8M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI HUGANIR, RICHARD L · 1985 to 2019
$37.6M
Parthanatos, AIF and PAAN-1 in Neuronal InjuryR37NS067525 · NINDS · JOHNS HOPKINS UNIVERSITY · PI DAWSON, TED M., DAWSON, VALINA L. · 2015 to 2021
$5.3M
NIA NIH HHS P50 AG005146NINDS NIH HHS P50 NS038377NINDS NIH HHS R37 NS067525
6 · The paper itself

Abstract

Genetic studies have shown the association of Parkinson's disease with alleles of the major histocompatibility complex. Here we show that a defined set of peptides that are derived from α-synuclein, a protein aggregated in Parkinson's disease, act as antigenic epitopes displayed by these alleles and drive helper and cytotoxic T cell responses in patients with Parkinson's disease. These responses may explain the association of Parkinson's disease with specific major histocompatibility complex alleles.

Indexed as

AgedAged, 80 and overAllelesalpha-SynucleinAmino Acid SequenceAutoimmunityEpitopes, T-LymphocyteFemaleHLA AntigensHumansMaleMiddle AgedParkinson DiseasePeptide FragmentsT-LymphocytesT-Lymphocytes, Cytotoxicalpha-SynucleinEpitopes, T-LymphocyteHLA AntigensPeptide Fragments

Identifiers

PMID28636593
PMCPMC5626019
OpenAlexW2638382976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.